Condor Software, the AI platform for biopharma R&D teams, has introduced AI-powered investigator grants intelligence, a new capability that lets sponsors ingest payment data from their CROs and site-payment vendors and automatically reconcile it against their own trial activity and site contracts. R&D teams can now instantly see site-level cost and performance patterns, assess costs relative to site performance, and improve forecasting accuracy — bringing greater financial visibility and accountability to investigator grants spend.
Investigator grants account for up to half of total per-trial cost, and clinical activity can generate tens of thousands of payment lines in single mid-sized trial. Most teams outsource grant payments to CROs or payments vendors who typically share summary reports — sometimes only single dollar figure — with no visibility into which visits, procedures, or site fees it represents. Without line-level verification, sponsors pay for visits that never happened, procedures billed at off-contract rates, and duplicate charges, and struggle to forecast and understand site performance.
"Every investigator grant has three versions of the truth: what the contract says should happen, what your own trial data says happened, and what the vendor says happened," said Condor VP of Product Nim Fox. "Sponsors already had the first two in Condor. Vendor-level data was the missing piece. But even when teams can get it, it arrives in the vendor's format, split and combined differently from how they track the work. We use AI to close that gap, so teams know whether they're being overbilled, what's missing, and what's coming, instead of taking the vendor's number on faith, and can then build more accurate forecasts. Today's announcement is another great example of how we are leveraging AI to automate manual work that slows biopharma R&D teams down."
How AI-Powered Investigator Grants Intelligence Works: Sponsors ingest vendor payment reports, procedure data, and visit data, from accrual reports to detailed site invoices, directly into Condor. Built on Condor's clinical and financial knowledge graph, Biopharma R&D Graph, platform's AI normalizes each vendor's format and maps every line to sponsor's EDC activity, protocols, and site contracts. Once reconciled, surfaces overbilling flagged against contracted rates and duplicates, missing payments with no activity, sites paid with no subject enrolled, completed work not yet invoiced, and patterns over time including sites consistently overbilling and share of spend going to startup versus patient activity.
"The next step is moving from analysis on demand to continuous monitoring," said Fox. "Condor's AI will watch payment and performance data as it arrives and flag anomalies the moment they appear. And the site-level evidence it builds gives sponsors a stronger position when they negotiate CRO change orders."
AI-powered investigator grants intelligence available now. Launch extends AI capabilities Condor introduced with Clinical Finance Agent in September, and expands platform's functionality as foundation for more autonomous agentic workflows.
About Condor
Condor Software is AI platform for biopharma R&D teams automatically centralizing clinical, operational, and financial data automating workflows like budgeting, forecasts, month-end closes, accruals, and change order management. Founded by Jen Kyle backed by Insight Partners, Felicis, 645 Ventures, trusted by leading biopharma including Acadia, BridgeBio, Madrigal.
